These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 8743204)
1. Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialysis. de Sancho M; Lema MG; Amiral J; Rand J Thromb Haemost; 1996 Apr; 75(4):695-6. PubMed ID: 8743204 [No Abstract] [Full Text] [Related]
2. The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis. Carrier M; Knoll GA; Kovacs MJ; Moore JC; Fergusson D; Rodger MA Thromb Res; 2007; 120(2):215-20. PubMed ID: 17098277 [TBL] [Abstract][Full Text] [Related]
3. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin. Adiguzel C; Bansal V; Litinas E; Cunanan J; Iqbal O; Nelson K; Kannan M; Hoppensteadt D; Fareed J Clin Appl Thromb Hemost; 2009; 15(2):145-51. PubMed ID: 19357103 [TBL] [Abstract][Full Text] [Related]
4. Prevalence of the antiheparin-platelet factor 4 antibody in hemodialysis (HD) patients and its effects upon dialysis access. Wallace K; Dasgupta I; Stratton J; Johnston P; Parry R Clin Nephrol; 2010 Nov; 74(5):409-10. PubMed ID: 20979952 [No Abstract] [Full Text] [Related]
5. Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. Nakamoto H; Shimada Y; Kanno T; Wanaka K; Matsuo T; Suzuki H Hemodial Int; 2005 Oct; 9 Suppl 1():S2-7. PubMed ID: 16223438 [TBL] [Abstract][Full Text] [Related]
6. The presence of heparin-platelet factor 4 antibodies as a marker of hypercoagulability during hemodialysis. Yu A; Jacobson SH; Bygdén A; Egberg N Clin Chem Lab Med; 2002 Jan; 40(1):21-6. PubMed ID: 11916267 [TBL] [Abstract][Full Text] [Related]
7. Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis. Davenport A Am J Kidney Dis; 2009 Aug; 54(2):361-74. PubMed ID: 19481318 [No Abstract] [Full Text] [Related]
8. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Amiral J; Bridey F; Dreyfus M; Vissoc AM; Fressinaud E; Wolf M; Meyer D Thromb Haemost; 1992 Jul; 68(1):95-6. PubMed ID: 1514184 [No Abstract] [Full Text] [Related]
9. Anti-heparin-platelet factor 4 antibodies are associated with arterial and venous thrombosis in patients with maintenance haemodialysis. Tan Y; Cao L; Lv JC; Yan Y; Zuo L; Wang M; Yu L; Yu F; Zhao MH Thromb Haemost; 2009 Dec; 102(6):1282-4. PubMed ID: 19967164 [No Abstract] [Full Text] [Related]
11. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex. Francis JL Semin Thromb Hemost; 2004 Jun; 30(3):359-68. PubMed ID: 15282659 [TBL] [Abstract][Full Text] [Related]
12. The presence of antibodies against a PF4-heparin complex in patients on haemodialysis. Boon DM; van Vliet HH; Zietse R; Kappers-Klunne MC Thromb Haemost; 1996 Sep; 76(3):480. PubMed ID: 8883294 [No Abstract] [Full Text] [Related]
13. When heparin causes thrombosis: significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients. Chang JJ; Parikh CR Semin Dial; 2006; 19(4):297-304. PubMed ID: 16893407 [TBL] [Abstract][Full Text] [Related]
14. Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. Wanaka K; Matsuo T; Matsuo M; Kaneko C; Miyashita K; Asada R; Matsushima H; Nakajima Y J Thromb Haemost; 2010 Mar; 8(3):616-8. PubMed ID: 20050999 [No Abstract] [Full Text] [Related]
15. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Juhl D; Eichler P; Lubenow N; Strobel U; Wessel A; Greinacher A Eur J Haematol; 2006 May; 76(5):420-6. PubMed ID: 16466367 [TBL] [Abstract][Full Text] [Related]
16. Predictors for the development of elevated anti-heparin/platelet factor 4 antibody titers in patients undergoing cardiac catheterization. Yeh RW; Everett BM; Foo SY; Dorer DJ; Laposata M; Van Cott EM; Jang IK Am J Cardiol; 2006 Aug; 98(3):419-21. PubMed ID: 16860036 [TBL] [Abstract][Full Text] [Related]
17. Anti-heparin-platelet factor 4 antibody is a risk factor for vascular access obstruction in patients undergoing hemodialysis. Lee EY; Hwang KY; Yang JO; Hong SY J Korean Med Sci; 2003 Feb; 18(1):69-72. PubMed ID: 12589090 [TBL] [Abstract][Full Text] [Related]
18. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Greinacher A; Gopinadhan M; Günther JU; Omer-Adam MA; Strobel U; Warkentin TE; Papastavrou G; Weitschies W; Helm CA Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2386-93. PubMed ID: 16873726 [TBL] [Abstract][Full Text] [Related]
19. Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis. Matsuo T; Kobayashi H; Matsuo M; Wanaka K; Nakamoto H; Matsushima H; Sakai R Pathophysiol Haemost Thromb; 2006; 35(6):445-50. PubMed ID: 17565238 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of heparin-dependent platelet antibodies in children after cardiopulmonary bypass. Hanson SJ; Punzalan RC; Ghanayem N; Havens P Pediatr Crit Care Med; 2007 Jul; 8(4):358-61. PubMed ID: 17545932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]